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Abstract Oligonucleotide-peptide conjugates have several ap-
plications, including their potential use as improved antisense
agents for interfering with the RNA function within cells. In
order to provide robust and generally applicable conjugation
chemistry, we developed a novel approach of fragment coupling
of pre-synthesized peptides to the 2P-position of a selected
nucleotide within an otherwise protected oligonucleotide chain
attached to a solid support.
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1. Introduction
Considerable attention has been devoted recently to the
design of oligonucleotide analogues to improve their antisense
characteristics and eventually create therapeutic remedies of
greatly increased e⁄ciency. Examples include various modi¢-
cations introduced at the base, sugar and phosphate moieties
to attain nuclease resistance, enhanced duplex stability and
cellular uptake [1]. Completely satisfactory solutions to all
these problems are not yet available. Nevertheless, one can
be optimistic that this research e¡ort will bear fruit.
One general form of modi¢cation is to covalently attach a
large variety of speci¢c ligands to the oligonucleotides.
Among the possible appendages are peptides, whose conjuga-
tion to DNA fragments produces oligonucleotide-peptide hy-
brids. For example, oligonucleotides have been linked to a
number of peptides to enhance the cellular membrane perme-
ability [2], generate speci¢c cleavage of nucleic acids [3] and
provide attachment sites for non-radioactive reporter groups
[4].
A number of methods of peptide-oligonucleotide conjuga-
tion have been described recently, none of which is su⁄ciently
general or convenient. Two chemical schemes have mainly
been adopted. In the ¢rst one, conjugation of di¡erent pep-
tides to modulate the function of oligonucleotides often re-
quires introducing a suitable tether containing the reactive
group (e.g. -SH or -NH2) to the oligonucleotide and post-
synthetically adding the peptide as an active intermediate,
followed by carrying out the coupling reaction in aqueous
medium [5,6]. This includes utility of fully deprotected and
puri¢ed species. Although this method is widely used, it suf-
fers from some disadvantages, such as poor coupling e⁄cien-
cies and several steps needed for the puri¢cation of the con-
jugate [7].
An alternative approach is to carry out the conjugate syn-
thesis in a linear fashion on a single solid-phase support [8,9].
The di⁄culty is partly the need to ¢nd a combination of
compatible protecting groups for the oligonucleotide and pep-
tide moieties during sequential assemblies. All these draw-
backs restrict the choice of conjugates that can be prepared.
In this paper, we describe a fragment strategy for the prep-
aration of oligonucleotide-peptide conjugates that involves
coupling of a NK-protected peptide through its carboxy-termi-
nus to the assembled solid support-bound oligonucleotide
after generating the free amino group in the solid support,
while other protecting groups are intact and oligonucleotide
is still linked to the polymer support. A fragment coupling
route was ¢rst described by Grandas and coworkers [10] for
the preparation of peptide-oligonucleotide conjugates with a
N-acylphosphoramidite union. Peyrottes et al. [11] have re-
cently demonstrated the use of a fragment route for the cou-
pling of peptide fragments to support-bound protected oligo-
nucleotide through the formation of an amide linkage. This
methodology takes advantage of mild reaction conditions
which are convenient for the preparation of hybrid molecules.
The utilization of these methods, however, is limited because
peptides were conjugated at the 5P-terminus of a protected
oligonucleotide. Furthermore, a more £exible approach may
be needed where a peptide can be attached at any site along
an oligonucleotide chain, since the site of conjugation may
signi¢cantly in£uence the cellular uptake properties. Our gen-
eral idea is based upon synthesizing a suitably protected nu-
cleoside bearing a side arm which is attached to the 2P-posi-
tion of a carbohydrate residue on one end and terminates in a
masked primary amino group. Once synthesized, a conven-
iently prepared phosphoramidite derivative replaces one of
the standard monomers in a solid-phase synthetic procedure.
The advantage of this approach is that ‘linker arm’ nucleo-
sides can be incorporated into the DNA at precisely de¢ned
sites and the subsequent binding of the peptide occurs only at
those sites.
2. Materials and methods
2.1. General procedures
2-Cyanoethyl-N,N-diisopropyl phosphoramidites and controlled
pore glass supports derivatized with protected deoxynucleosides
were purchased from Applied Biosystems. 1H-tetrazole was purchased
from Pharmacia. N-hydroxysuccinimide, O-(benzotriazol-1-yl)-N,
N,NP,NP-tetramethyluronium hexa£uorophosphate (HBTU) and N-
(9-£uorenylmethoxycarbonyloxy)succinimide were obtained from Al-
drich. Dicyclohexylcarbodiimide (DCC) was purchased from Sigma.
Anhydrous solvents were obtained using standard techniques.
1H-NMR spectra were recorded on a VXR-400 spectrometer (Var-
ian). Chemical shifts (N) are expressed in parts per million from tetra-
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methylsilane. Electrospray mass spectra were obtained using a Finni-
gan MAT LCQ spectrometer. MALDI mass analyses were performed
on a Voyager DE spectrometer (PerSeptive Biosystems).
2.2. Preparation of modi¢ed nucleoside 3P-phosphoramidite
9-(2-Amino-2-deoxy-5-O-dimethoxytrityl-L-D-arabinofuranosyl)-N6-
benzoyladenine 1 was prepared from adenosine as described earlier
[12]. N-(9-Fluorenylmethoxycarbonyl)-L-alanine and N-(9-£uorenyl-
methoxycarbonyl)-L-alanine N-hydroxysuccinimide ester 2 were syn-
thesized according to literature procedures [13,14].
9-(2-Deoxy-2-(N-(9-£uorenylmethoxycarbonyl)-3-aminopropionyl)-
amino-5-O-dimethoxytrityl-L-D-arabinofuranosyl)-N6-benzoyladenine
3. Compound 1 (0.67 g, 1 mmol) was dissolved in dry dioxane (10 ml)
and N-(9-£uorenylmethoxycarbonyl)-L-alanine N-hydroxysuccinimide
ester 2 (0.42 g, 1 mmol) was added on stirring. The reaction was then
stirred for 8 h at room temperature. After removal of solvent and
puri¢cation by column chromatography on silica gel, compound 3
was obtained (0.82 g, 85%). 1H-NMR (CDCl3, N) : 8.56 (s, 1H, H-
8), 8.22 (s, 1H, H-2), 7.97^6.75 (m, 26H, Fmoc, 4P,4Q-dimethoxytrityl,
N6-benzoyl), 6.44 (d, 1H, H-1P, J10 ;20 5.9 Hz), 4.75 (m, 1H, H-2P),
4.40^4.11 (m, 4H, H-3P, H-9 of Fmoc and Fmoc-CH2), 3.80 (m,
1H, H-4P), 3.55 (m, 2H, H-5Pa,b), 3.05 (m, 2H, CH2L of L-Ala),
2.50 (t, 2H, CH2K of L-Ala, JCH2K;CH2L 6.7 Hz). ESI mass spectrom-
etry (MS): calculated for C56H51N7O9 966.06. Found: m/z 966.1
(M), 967.1 (M+H).
Phosphitylation of 3 was carried out according to Barone et al. [15].
Yield of 4 : 95%. ESI MS: calculated for C65H68N9O10P 1166.28.
Found: m/z 1166.3 (M). 31P-NMR (CDCl3, N): 3148.86, 3149.18.
2.3. Oligodeoxynucleotide synthesis and characterization
Oligodeoxynucleotides were assembled using an Applied Biosystems
380B DNA synthesizer following the manufacturer’s recommenda-
tions with the cyanoethyl phosphoramidite procedure. For couplings
with modi¢ed phosphoramidite 4, a 0.15 M concentration in anhy-
drous acetonitrile was used and the coupling wait time was increased
to 600 s.
The oligonucleotides were deprotected, puri¢ed and analyzed by
reversed phase high performance liquid chromatography (HPLC)
with no modi¢cations to the normal procedures [12].
2.4. Peptide synthesis and characterization
Synthesis of peptide fragments was carried out by Fmoc solution-
phase chemistry. Peptide couplings employed NK-Fmoc-protected
amino acid building blocks, dicyclohexylcarbodiimide and hydroxy-
benzotriazole (HOBT) in DMF. Fmoc peptides were analyzed and
isolated as described earlier [16].
2.5. Coupling of peptide fragments to oligodeoxynucleotides
The Fmoc protecting group was ¢rst removed from the support-
bound oligodeoxynucleotide by treatment with morpholine for 1 h at
room temperature. The supernatant was then decanted and support
was rinsed with DMF (2U100 Wl). Finally, to the oligodeoxynucleo-
tide-resin were added: Fmoc peptide (¢ve equivalents compared to
oligodeoxynucleotide), HBTU (one equivalent compared to peptide)
and N,N-diisopropylethylamine (10 equivalents) in 100 Wl DMF. The
solution was then shaken from time to time for 1.5 h at room temper-
ature. Following removal of supernatant, the solid support was
washed with DMF (3U100 Wl) and then with ethanol (2U100 Wl).
Cleavage from polymer support, deprotection, analytical and prepa-
rative HPLC of conjugates were carried out as mentioned above for
oligonucleotides. Conjugate molecular masses were determined by
MALDI-TOF MS (Table 1).
3. Results and discussion
Our initial studies have concentrated on preparation of a
modi¢ed nucleoside building block in which linker is incorpo-
rated for attachment of the peptide fragment. A spacer arm of
some length is desirable to separate the inserted functionality
from the nucleic acid sequence, especially if the oligomer is to
be hybridized to a complementary target. The ideal location
for conjugation of di¡erent ligands is at sites which have steric
tolerance in a double helix. The 2P-position of a sugar ring is
not involved in hydrogen bonding so the attachment of a
linker molecule or peptide fragment should not drastically
alter the stability of the nucleic acid complex. For this reason,
and because of simple synthesis procedures being used in its
preparation, amine linker arm nucleoside was accepted by us.
We recently reported [12] the synthesis of the new type of
sugar-modi¢ed oligodeoxynucleotides containing 9-(2-amino-
2-deoxy-L-D-arabinofuranosyl)adenine residues. The 2P-ami-
no-2P-deoxyarabinoadenosine residues were shown to induce
the increased resistance of modi¢ed oligomers towards the
enzymatic cleavage and provide insigni¢cant destabilization
of DNA duplexes. Therefore, the functionalization of oligo-
nucleotides by incorporating 2P-aminonucleoside may provide
a way to link various groups to the carbohydrate moiety. A
2P-amido bond may be expected to be chemically and meta-
bolically stable and not interfering with oligonucleotide syn-
thesis. Thus 2P-amino-2P-deoxyarabinoadenosine was selected
as precursor of amino linker containing nucleoside.
The length of the linker molecule is very critical for a spe-
ci¢c use. Using our previous expertise in synthesis of cross-
linked DNA duplexes [17], L-alanine was proposed to incor-
porate an amino group at the 2P-position. Preparation of the
linker molecule requires appropriate protection of the amino
group. It must be chemically blocked but speci¢cally remov-
able without a¡ecting the remaining protecting group on the
oligonucleotide or cleaving the linkage to the solid-phase. In
order to insert amino linker containing nucleosides at any
position of oligonucleotides which can be applied for solid-
phase conjugation chemistry, we introduced a Fmoc protect-
ing group. The Fmoc group is ideal for protection of primary
amines during oligonucleotide synthesis since it is stable to
hydrolysis in the organic acids used to remove 5P-O-dimeth-
oxytrityl groups in each cycle, yet, it undergoes rapid non-
Fig. 1. Synthesis of the phosphoramidite derivative of 2P-amino link-
er containing nucleoside analogue.
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hydrolytic cleavage on treatment with simple bases (piper-
idine, morpholine), usually in polar solvents such as DMF
or acetonitrile, to liberate an amino group in the free base
form. Therefore, we envisioned that these conditions would
be mild enough to preclude removal of L-cyanoethyl protect-
ing groups from internal phosphates or damaging the linkage
between the solid support and the oligonucleotide. Prior to
the synthesis of oligodeoxynucleotide chains, the stability of
the standard succinyl linkage to the morpholine was analyzed.
After the assembly of the dinucleoside phosphate TT, the
support was treated with morpholine. In this case, the succinyl
linkage was found to be stable under these conditions (HPLC
analysis). We also observed a good stability of the L-cyano-
ethyl protecting group when morpholine was added to
tritylated dimer TT synthesized by the phosphoramidite meth-
od in solution [18] (TLC analysis).
Synthesis of 2P-deoxyadenosine analogue bearing amino
linker was carried out as shown in Fig. 1. Compound 1 was
made starting from adenosine as previously described [12].
Thus, reaction of L-alanine with N-(9-£uorenylmethoxycarbo-
nyloxy)succinimide in dioxan/water (1:1) a¡orded a 95% yield
of N-(9-£uorenylmethoxycarbonyl)-L-alanine. The product re-
acted with N-hydroxysuccinimide in the presence of dicyclo-
hexylcarbodiimide in tetrahydrofuran solution to give the cor-
responding succinimidyl derivative 2 in a 75% yield. The 2P-
amino group of the appropriately blocked nucleoside 1 re-
acted selectively with 2 to provide functionalized linker arm
nucleoside analogue 3 which was converted to its 3P-phos-
phoramidite 4 by standard methods [15].
Upon completion of each oligonucleotide synthesis, the 5P-
O-dimethoxytrityl group was left on to aid reversed phase
HPLC puri¢cation. The feasibility of the synthesis was ¢rst
tested by taking a heptamer, 5P-TTTTA*TT-3P (I) (A*, 9-(2-
(3-aminopropionyl)amino-2-deoxy-L-D-arabinofuranosyl)ade-
nine), as a model sequence. The strategy was extended to the
12-mer 5P-GACCA*CCGCGCT-3P (II), complementary to
part of the 5S RNA from Escherichia coli. When modi¢ed
phosphoramidite synthon 4 was used, standard procedures
for synthesis with normal ones had to be altered by extending
Table 1
MS characterization of oligonucleotide-peptide conjugates and percentage yields in the coupling reactions
Oligonucleotide/peptide 5P-GACCACCGCGCT-3P
Abbreviations Empirical formula Expected m/z found Yielda, %
Leu-Gly c1 C125H166N49O72P11 3 847.68 3 846.88 90.3
Tyr-D-Ala-Phe-Gly c2 C140H178N51O75P11 4 115.96 4 114.01 81
aYields are based on HPLC analysis.
Fig. 2. Reaction scheme for the preparation of oligonucleotide-pep-
tide conjugates.
Fig. 3. HPLC pro¢les of (a) the reaction mixture resulting from sol-
id-phase coupling of NK-Fmoc-Leu-Gly to support-bound 12-mer
(II), (b) the reaction mixture (as shown in a) co-injected with puri-
¢ed 12-mer (II), (c) puri¢ed oligonucleotide-peptide conjugate (c1,
Table 1). For conditions, see Section 2. Peak 1, 5P-CCGCGCT-3P
(the by-product, failure sequence); peak 2, c1; peak 3, 5P-GAC-
CA*CCGCGCT-3P.
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the coupling time to 10 min. As a further check on the syn-
thetic procedure, one batch of either synthesis was depro-
tected by standard protocols and analyzed by equidistant
ion-pair reversed phase HPLC [19]. After synthesis, an aliquot
of II was deprotected and puri¢ed by reversed phase HPLC.
A major component corresponding to the desired product was
observed (data not shown) and characterized by MALDI-
TOF MS.
In order to certify the existence of the amino group, 7- and
12-mers were treated with acetic anhydride to give acetylated
oligonucleotides, retention times of which were somewhat lon-
ger than that of corresponding oligomers with a free amino
group (data not shown).
The blocked oligodeoxynucleotide attached to the con-
trolled pore glass support was deprotected to unmask the
tethered amino group in the solid support (Fig. 2). In this
case, the Fmoc protecting group on the L-alanine residue
was removed by treatment with morpholine for 1 h.
To illustrate the solid-phase synthesis of oligonucleotide-
peptide conjugates, we chose two short peptides, NK-Fmoc-
Leu-Gly and NK-Fmoc-Tyr-D-Ala-Phe-Gly, that contain a C-
terminal glycine, where racemization cannot take place. Pep-
tide fragments were prepared using standard DCC/HOBT-
mediated couplings [20] of N-Fmoc-protected K-amino acids
in solution. During the past two decades, a number of di¡er-
ent reagents have been used for amide bond formation. Of
these, activator HBTU is one of the best reagents for in situ
formation of hydroxybenzotriazolyl esters [21]. It enables cou-
plings to be carried out smoothly and the free aliphatic hy-
droxyl function of tyrosine is not a¡ected. In our procedure,
the support-bound oligodeoxynucleotide reacted with a solu-
tion of Fmoc peptide in dimethylformamide in the presence of
HBTU and triethylamine for 1.5 h. An additional advantage
of our process is the facile puri¢cation of the ¢nal product
containing a terminal 5P-O-dimethoxytrityl group by reversed
phase HPLC. The conjugate molecule was analyzed by equi-
distant ion-pair reversed phase HPLC and by MALDI-TOF
MS (Table 1). For coupling reactions to the support-bound
amino-functionalized oligonucleotide (II), good yields were
obtained for both dipeptide Leu-Gly and tetrapeptide Tyr-D-
Ala-Phe-Gly conjugates. An example is shown in Fig. 3. It
was observed that the major peak corresponding to the pep-
tide conjugate of oligonucleotide (peak 2) was retarded in
mobility compared to control oligonucleotide functionalized
with a primary amino group at its 2P-position (peak 3).
To sum up, we developed a new £exible strategy where
protected peptide fragments were coupled to solid-phase-
bound, fully protected oligodeoxynucleotides to form irrever-
sible covalent linkages. The formation of a stable amide bond
was achieved by conjugation of the C-terminus of the peptide
to the 2P-amino-functionalized oligonucleotide. The 2P-func-
tionalization methodology proved to be extremely valuable
for preparing two peptide conjugates of oligodeoxynucleoti-
des. Once high yields have been obtained for short peptide
conjugations, it will be possible to attach longer peptides. The
studies will be considerably extended to include peptide con-
jugates of oligonucleotide analogues that are likely to be use-
ful as antisense agents.
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